Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide.
Gilead’s operation in Amsterdam is responsible for medical, sales and marketing support for our products throughout the Netherlands.
Since 2013, the Dutch Transparency Register makes financial links between pharmaceutical manufacturers and professionals, institutions (including patient organizations) or joint ventures public. The information for 2017 regarding the financial support of Gilead Sciences can be found in the Transparency Register (www.transparantieregister.nl). For a listing of previous years’ support, click here.
However, the costs of research and development are not included in this transparency register. In order to make research and development costs as transparent as possible, EFPIA (European Federation of Pharmaceutical Industries and Associations) asked all member pharmaceutical companies to publish their research and development costs on their own websites (click here for the EFPIA Disclosure Code). The costs are made public on an aggregated basis in each reporting period. The disclosures are made on an annual basis and each reporting period covers a full calendar year (the 'reporting period').
The amount paid in 2017 is € 1.221.682,94
Relationships with Patient Organizations
Gilead Sciences provided support to patient organisations via sponsorship agreements or unrestricted grants.
The information over 2017 regarding the financial support of Gilead Sciences to patient organisations can be found in the Transparency Register (
For a listing of previous years’ support, click here.
This page is intended for visitors outside of the United States.